Outlook Therapeutics Inc (OTLK)

[H2R]

BTIG: $50 Target Price

https://www.marketbeat.com/instant-alerts/nasdaq-otlk-upgrade-2024-03-27/

A number of analysts are starting to up their price targets. I spaced up for better legibility:

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) was upgraded by stock analysts at BTIG Research from a "neutral" rating to a "buy" rating in a research note issued on Wednesday, Marketbeat.com reports. The brokerage presently has a $50.00 price target on the stock. BTIG Research's price objective would suggest a potential upside of 476.04% from the company's current price.

OTLK has been the subject of a number of other research reports.
Ascendiant Capital Markets raised their price objective on Outlook Therapeutics from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Friday, December 29th.

Capital One Financial reiterated an "overweight" rating on shares of Outlook Therapeutics in a research report on Friday, February 16th.

Guggenheim upgraded Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $40.00 target price for the company in a research report on Thursday, January 25th.

Brookline Capital Management upgraded Outlook Therapeutics from a "hold" rating to a "buy" rating and set a $31.40 target price for the company in a research report on Thursday, January 25th.

Finally, HC Wainwright boosted their price objective on Outlook Therapeutics to $30.00 and gave the company a "buy" rating in a research report on Monday.

One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company.

According to data from MarketBeat.com, Outlook Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $46.43.

Best of luck with your investments!